Randomized Phase II Study of the PDGFRα Antibody Olaratumab Plus Liposomal Doxorubicin Versus Liposomal Doxorubicin Alone in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer

BMC Cancer - United Kingdom
doi 10.1186/s12885-018-5198-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

ENGOT-ov-6/TRINOVA-2: Randomised, Double-Blind, Phase 3 Study of Pegylated Liposomal Doxorubicin Plus Trebananib or Placebo in Women With Recurrent Partially Platinum-Sensitive or Resistant Ovarian Cancer

European Journal of Cancer
Cancer ResearchOncology
2017English

Non‑pegylated Liposomal Doxorubicin for Patients With Recurrent Ovarian Cancer: A Multicentric Phase II Trial

Oncology Letters
Cancer ResearchOncology
2016English

Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Cancer
Cancer ResearchOncology
2016English

Randomized Comparison of Doxorubicin Alone Versus Ifosfamide Plus Doxorubicin or Mitomycin, Doxorubicin, and Cisplatin Against Advanced Soft Tissue Sarcomas.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
1993English

Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

Archives of Dermatology
2008English

Gemcitabine Plus Liposomal Doxorubicin for Relapsed Refractory T-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Phase I Study of Romidepsin and Liposomal Doxorubicin in Relapsed or Refractory T-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pegylated Liposomal Doxorubicin for Platinum-Resistant or Refractory M�llerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube and Peritoneal Carcinoma): A Single-Institutional Experience

Oncology Letters
Cancer ResearchOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy